Establishment Of HD Immune And Publication Of The Latest Preclinical Data

VIENNA--( BUSINESS WIRE )-- HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington's disease, is a joint venture between Dr. Stefan Bartle and Dr. Lionel Wightman. Two people announced that they will start a business as founders. HDI acquired the Huntington's disease program patents and assets from AFFiRiS AG. HDI also completed a pre-seed funding round with an Austrian business angel and secured a pre-seed grant from Austria Bildshafts Services (AWS). Additionally, HDI has successfully applied to the Comet24 program of the Austrian Center for Industrial Biotechnology (acib), enabling collaboration with the Institute of Molecular Biotechnology (BOKU, Vienna University of Natural Resources and Life Sciences) on HDI's research programs. We announced what happened.

Stefan Bartle, CEO of HDI, said: “With the acquisition of the Huntington's disease program that I previously developed at AFFiRiS AG, HD Immune will be able to move from the get-go to an unprecedented step to demonstrate the therapeutic efficacy of our lead monoclonal antibody C6-17 in a transgenic model of Huntington's disease. This means that we have excellent preclinical data, which we have just recently published.We are currently working on a drug that aims to slow the progression of Huntington's disease and improve the quality of life for patients. We are proceeding with the humanization process of this antibody in order to develop a treatment for the mutant huntingtin protein.Currently, there are no treatments that can directly treat the mutant huntingtin protein."

HD Immune's new preclinical study report can be downloaded from our webpage www.hdimmune.com .

HD immunity and Huntington's disease

Huntington's disease (HD) is a fatal neurodegenerative disease that usually begins clinically in the fourth decade of life and progresses to severe neurological and psychiatric exacerbations. HD is a rare single-gene disease in which mutated huntingtin protein (mtHTT), which is structurally altered due to genetic mutations, forms aggregates in the brain.

HD Immune is developing antibodies that target this mutant protein and remove it from the body. HDI's proprietary lead antibody, mAB C6-17, reduced mtHTT in the blood, organs, and central nervous system, as well as improved exercise performance in transgenic mice expressing the human mutant protein. Based on these results, HD Immune plans to further develop antibodies for human treatment to alleviate symptoms in patients.

The official version of this press release is the original language version. Translated language versions are provided for the convenience of the reader and have no legal effect. When using a translated language version as a document, please compare it with the original language version, which is the only legally enforceable version.

Contacts

HD Immune GmbH
office@hdimmune.com
www.hdimmune.com